1
|
Fulla M, Szafarowski T, Frias-Gomez J, Quiros B, Clavero O, Gomà M, Pavon MA, Jurek-Matusiak O, Lares HR, Mañós M, Alemany L, Mena M, Gonzalez X. Correction to: Human Papillomavirus and Factors Associated with Recurrence in Sinonasal Inverted Papillomas from Poland and Spain. Head Neck Pathol 2020; 14:768-770. [PMID: 32040821 PMCID: PMC7413926 DOI: 10.1007/s12105-020-01138-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The original version of this article unfortunately contained a mistake. Three values in Table 1 were incorrect. In "months of recurrence", range row, the intervals should be in numbers. They should read as 3-83 instead of Mar-83, 9-83 instead of Sep-83 and 3-36 instead of Mar-36. The corrected Table 1 is given below. The original article has been corrected.
Collapse
Affiliation(s)
- M Fulla
- Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
| | - T Szafarowski
- Department of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Warsaw, Poland
| | - J Frias-Gomez
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain
- Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - B Quiros
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain
- Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - O Clavero
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain
- Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - M Gomà
- Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
- Department of Pathology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M A Pavon
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain
- Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - O Jurek-Matusiak
- Department of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Warsaw, Poland
| | - H R Lares
- Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
- Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - M Mañós
- Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
- Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
- University of Barcelona, Barcelona, Spain
| | - L Alemany
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain
- Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - M Mena
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain
- Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - X Gonzalez
- Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
- Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
2
|
Fulla M, Szafarowski T, Frias-Gomez J, Quiros B, Clavero O, Gomà M, Pavon MA, Jurek-Matusiak O, Lares HR, Mañós M, Alemany L, Mena M, Gonzalez X. Human Papillomavirus and Factors Associated with Recurrence in Sinonasal Inverted Papillomas from Poland and Spain. Head Neck Pathol 2020; 14:758-767. [PMID: 31916205 PMCID: PMC7413944 DOI: 10.1007/s12105-019-01125-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Accepted: 12/30/2019] [Indexed: 12/11/2022]
Abstract
Sinonasal inverted papilloma (SNIP) is a benign but locally aggressive tumor that has a tendency for recurrence and malignant transformation. The role of human papillomavirus (HPV) in SNIP is controversial. To determine the HPV-DNA prevalence and type distribution in SNIP in two different geographic areas and assess the association between SNIP recurrence and HPV infection, as well as additional potential etiologic factors. Two retrospective cohorts of SNIP patients from Poland and Spain were evaluated. Demographic, tobacco/alcohol use, clinical, and follow-up data were collected. All samples were subject to histopathologic evaluation, DNA quality control, and HPV-DNA detection by PCR. HPV-DNA positive samples and a random sample of HPV-DNA negative cases were further subject to p16INK4a analysis. Proportional-hazards models were used to evaluate the risk of recurrence by selected variables. Seventy-nine SNIP patients (46 from Spain diagnosed between 1995 and 2014, and 33 from Poland diagnosed between 2012 and 2017) were included in the study. HPV-DNA was detected in four patients (5.1%), two from each region, and all four were positive for the HPV11 subtype. Seventeen patients (21.5%) experienced recurrence, with a median time to recurrence of 14 months. No association was identified between lesional HPV-DNA positivity, toxic habits, Krouse stage, or malignant transformation and a higher risk of recurrence. The low prevalence of HPV-DNA in SNIPs suggests that HPV is not a main etiology for development of these lesions. With a lack of association between the evaluated factors and recurrence, further research with larger number of patients and additional biomarkers is warranted to further understand predisposing risk factors.
Collapse
Affiliation(s)
- M. Fulla
- grid.417656.7Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
| | - T. Szafarowski
- grid.13339.3b0000000113287408Department of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Warsaw, Poland
| | - J. Frias-Gomez
- grid.418701.b0000 0001 2097 8389Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) – L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
| | - B. Quiros
- grid.418701.b0000 0001 2097 8389Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) – L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - O. Clavero
- grid.418701.b0000 0001 2097 8389Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) – L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - M. Gomà
- grid.417656.7Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Department of Pathology, Hospital Universitari Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
| | - M. A. Pavon
- grid.418701.b0000 0001 2097 8389Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) – L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - O. Jurek-Matusiak
- grid.13339.3b0000000113287408Department of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Warsaw, Poland
| | - H. R. Lares
- grid.417656.7Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
| | - M. Mañós
- grid.417656.7Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain ,grid.5841.80000 0004 1937 0247University of Barcelona, Barcelona, Spain
| | - L. Alemany
- grid.418701.b0000 0001 2097 8389Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) – L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - M. Mena
- grid.418701.b0000 0001 2097 8389Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) – L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - X. Gonzalez
- grid.417656.7Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.417656.7Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|